Immune cells engineered to fight mesothelioma enter human testing
NCT ID NCT07510815
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests a new treatment for people with mesothelioma that cannot be removed by surgery or has come back after standard therapy. The treatment uses donor immune cells (natural killer cells) that are engineered in a lab to recognize and attack two proteins found on mesothelioma tumors. The study has two parts: first to find a safe dose, then to see if the treatment can shrink tumors. About 36 adults will take part.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- engineered immune cells (CAR-NK cells) targeting mesothelin and FAP proteins, plus chemotherapy drugs fludarabine and cyclophosphamide
- What this could lead to
- If it works, this could point toward a new treatment option for mesothelioma that is hard to treat with standard therapies.
- What could go wrong
- This is an early phase 1/2 trial with only 36 participants, so it is too soon to know if it will be effective or safe for many people. There are risks of serious side effects like cytokine release syndrome or organ inflammation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT PERITONEAL MESOTHELIOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking University Shenzhen Hospital
RECRUITINGShenzhen, Guangdong, 518036, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.